Ro Launches First Super Bowl Campaign to Scale GLP-1 Weight-Loss Business

New updates have been reported about Ro.

Ro is making its most aggressive consumer push to date with its first Super Bowl commercial, using Serena Williams’ personal GLP-1 results to anchor a new multi-channel campaign aimed at driving nationwide demand for its weight-loss offering. Under the banner “Healthier on Ro,” the initiative positions Ro at the center of the fast-growing GLP-1 market by showcasing clinically relevant outcomes—Williams reports losing 34 pounds in a year, improved blood sugar, a 30% reduction in cholesterol since 2021, and an associated 70% relative reduction in lifetime heart disease risk—all achieved through Ro’s GLP-1 program. Ro’s management frames these outcomes as representative of broader patient experience on its platform, where GLP-1 users typically see 14–20% weight loss in a year alongside improvements in metabolic and joint health, supporting Ro’s strategy to differentiate on measurable health impact rather than weight alone.

The campaign, debuting during Super Bowl LX on NBC and extending across TV, digital, and out-of-home channels, is designed to normalize GLP-1 usage and capture share as prices fall and both injectable and oral options expand access. Ro is leveraging Williams, fellow ambassador Charles Barkley—who lost 45 pounds in seven months—and several non-celebrity patients to underline both the scalability and inclusivity of its care model, reinforcing its position as a vertically integrated, direct-to-patient provider with nationwide telehealth, labs, and pharmacy capabilities. CEO Zach Reitano describes the Williams partnership as an early stage of a broader, long-term effort to grow Ro’s GLP-1 franchise and strengthen its brand as a trusted entry point for obesity and cardiometabolic care. For executives and investors, the move signals a significant marketing and brand investment intended to accelerate patient acquisition, deepen engagement in Ro’s end-to-end virtual care ecosystem, and expand its role in one of healthcare’s most consequential growth categories.